David Anderson

David Anderson has over 25 years of experience, including Co-Founder and Chief Scientific Officer of Proprius Pharmaceuticals (acquired by Cypress Bioscience) where he oversaw the personalized medicine services and successful CLIA/CAP certification; Chief Scientific Officer at Celgene Corporation/Signal Research Division; Senior Vice President of Research & Development and Co-Founder of Signal Pharmaceuticals; Senior Director of Drug Discovery and Experimental Therapeutics at Johnson & Johnson (J&J); Director of the J&J Labs at Scripps Research Institute; and Group Leader at Monsanto/GD Searle. He was a leader or on teams responsible for the development of 7 INDs, 2 NDAs and 4 drugs approved by the FDA, including J&J’s Procrit® (erythropoietin), a product that achieved peak annual sales of over $4 billion, Leustatin®, and Revlimid® for oncology and Zubrin® for veterinary arthritis. David has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory and immunomodulatory drugs, and has also refereed articles for peer-reviewed journals such as Science and The Journal of Rheumatology. He has a Ph.D. in Medical Microbiology and Immunology from the University of Missouri-Columbia.